Diar Cancer Research Results

Diar, Diarrhea: Click to Expand ⟱
Source:
Type:
Diarrhea often chemotherapy induced
Scientific Papers found: Click to Expand⟱
7402- Amla,    Traditional knowledge to clinical trials: A review on therapeutic actions of Emblica officinalis
- Review, Var, NA
*eff↑, E.officinalis is one of the major component in various health tonics, also exerts synergistic effects in enhancing the medicinal efficacy.
*antiOx↑, antioxidant, anticancer, immunomodulator, anti-inflammatory, cyto-protective properties
*AntiCan↑,
*Imm↑,
*Inflam↓, In trial phase I, oral doses of 3 capsules per day for two weeks showed significant immuno-stimulatory effects on cytotoxic T cells and natural killer cells.
*AntiArt↑, The present review analysed and summarized the pharmacological actions, experimental studies and clinical trials of E. officinalis with emphasis on its immuno-enhancer, antiinflammatory and anticancer activities
*Dose↝, The fruit of amla consists of many bioactive compounds including ellagic acid, chebulinic acid, apigenin, gallic acid, quercetin, chebulagic acid, isostrictiniin, corilagin, methyl gallate, luteolin etc
*VitC↑, It has been reported that 100 g of edible fruit provides 470–680 mg of Vit. C.
radioP↑, figure 1
*cardioP↑,
*GastroP↑,
*Wound Healing↑,
*Diar↓,
eff↑, They reported that IC50 of Amla alone and PE-AgNP were 30 mg/mL and 20 mg/mL respectively, while these nanoparticles demonstrated potential antiproliferative effect by oxidative stress, mitochondrial depolar ization, DNA damage and apoptotic functio
NK cell↑, Enhanced natural killer (NK) cell activity and antibody dependent cellular cytotoxicity
BAX↑, Up-regulation of Bax expression and down-regulation of Bcl-2 expression.Cell cycle arres
Bcl-2↓,
TumCCA↑,
Dose↝, Powdered amla fruit at dosage of 1, 2 or 3 g orally given with 30 ml water once daily in the morning after breakfast for 21 days

5627- Bif,    Efficacy and Safety of Probiotics as Adjunctive Therapy in Cancer Treatment: A Comprehensive Systematic Review and Meta-Analysis
- Review, Var, NA
Diar↓, Probiotic use was associated with a significant reduction in the incidence of diarrhea

5680- BML,    Anticancer properties of bromelain: State-of-the-art and recent trends
- Review, Var, NA
*Inflam↓, anticancer, anti-edema, anti-inflammatory, anti-microbial, anti-coagulant, anti-osteoarthritis, anti-trauma pain, anti-diarrhea, wound repair.
*Bacteria↓,
*Pain↓,
*Diar↓,
*Wound Healing↑,
ERK↓, Figure 1
JNK↓,
XIAP↓,
HSP27↓,
β-catenin/ZEB1↓,
HO-1↓,
lipid-P↓,
ACSL4↑,
ROS↑,
SOD↑,
Catalase↓,
GSH↓,
MDA↓,
Casp3↓,
Casp9↑,
DNAdam↑,
Apoptosis↑,
NF-kB↓,
P53↑,
MAPK↓,
APAF1↑,
Cyt‑c↓,
CD44↓,
Imm↑, Bromelain was also studied in the innate immune system, where it could enhance and sustain the process
ATG5↑,
LC3I↑,
Beclin-1↑,
IL2↓, bromelain in vitro experiments resulted in diminished amounts of IL-2, IL-6, IL-4, G-CSF, Gm-CSF, IFN-γ,
IL4↓,
IFN-γ↓,
COX2/PTGS2↓, proprietary bromelain extract could decrease IL-8, COX-2, iNOS, and TNF-α without affecting cell viability.
iNOS↓,
ChemoSen↑, Bromelain may increase the cytotoxicity of cisplatin in the treatment of breast cancer as reported in 2 studies with MDA-MB-231 and 4T1 Breast Tumor cell lines
RadioS↑, The size and weight of tumors in gamma-irradiated EST-bearing mice treated with bromelain decreased significantly with a significant amelioration in the histopathological examination
Dose↝, oral bromelain administration in breast cancer patients (daily up to a dose of 7800 mg)
other↓, The role of bromelain (in combination with papain, sodium selenite and Lens culinaris lectin) has been also tested as a complementary medicine on more than 600 breast cancer patients to reduce the side effects caused by the administration of the adju

5712- Brut,    The anti-inflammatory and antioxidant effects of bergamot juice extract (BJe) in an experimental model of inflammatory bowel disease
- in-vivo, IBD, NA
Diar↓, Treatment with BJe decreased the appearance of diarrhea and body weight loss.
Weight↑,
NF-kB↓, BJe reduced nuclear NF-κB translocation, p-JNK activation, the pro-inflammatory cytokines release, the appearance of nitrotyrosine and PAR in the colon and reduced the up-regulation of ICAM-1 and P-selectin.
p‑JNK↓,
ICAM-1↓,

5933- CAR,    Protective Effect of Carvacrol against Gut Dysbiosis and Clostridium difficile Associated Disease in a Mouse Model
- in-vivo, IBD, NA
*Diar↓, Carvacrol supplementation significantly reduced the incidence of diarrhea and improved the clinical and diarrhea scores in mice (p < 0.05).
*GutMicro↑, Microbiome analysis revealed a significant increase in Proteobacteria and reduction in the abundance of protective bacterial flora in antibiotic-treated and C.
*Dysb↓, Results suggest that CR could potentially be used to control gut dysbiosis and reduce C. difficile infection

5926- CAR,    An Updated Review of Research into Carvacrol and Its Biological Activities
- Review, Nor, NA - Review, AD, NA - Review, Asthma, NA
*Inflam↓, ic, analgesic, anti-inflammatory,antioxidant, and neuroprotective effects.
*antiOx↑,
*neuroP↑, Carvacrol has exhibited notable neuroprotective effects in experimental models of cognitiveimpairment and neurodegenerative diseases
*BioAv↑, advances in encapsulation andnanotechnology have enhanced its stability and bioavailability
*toxicity↓, Compared to phenol, carvacrol and thymol exhibitsignificantly lower toxicity. This makes carvacrol a safer alternative for various applications, frombiological agents to dietary supplements [
*Pain↓, Pain-Relieving Mechanisms of Car
*TRPV3↑, , carvacrol-induced TRPV3 activation enhances lipolysis in adipocytes via theNRF2/FSP1 a
*NRF2↑,
*Ca+2↑, TRPV3 activation in distal colon epithelial cells elevates intracellular Ca²⁺ levels and stimulates ATP release, implicating carvacrol in gut physiology and signaling
*ATP↑,
*5LO↓, s, including the inhibition of angiotensin-converting enzyme 2 (ACE2), lipoxygenase(LOX), and cyclooxygenase (COX) enzyme
*COX2/PTGS2↓,
PGE2↓, arvacrol’s anti-inflammatory effects involve theinhibition of prostaglandin E₂ (PGE₂) production via COX-2
*hepatoP↑, Carvacrol in Hepatic Protection as Natural Antioxidant
*AntiAg↑, Carvacrol has demonstrated significant antiplatelet activity, highlighting its potential therapeutic role in preventing thrombosis
*Diar↓, s essentialoil exhibited antidiarrheal effects in castor oil-induced diarrhea models, potentially mediated bymechanisms involving Kv channel activation and Ca²⁺ channel inhibition
*cardioP↑, em as promising nutraceutical candidates for alleviatingCVD-related complicat
*other↝, Carvacrol was evaluated for its therapeutic potential in managing erectile dysfunction (ED)associated with aging
*chemoPv↑, Chemopreventive Potential of Carvacrol in Detoxification pathways
*cognitive↑, carvacrol(0.5–2 mg/kg) and thymol significantly improved cognitive function in rats
*AChE↓, potent acetylcholinesterase inhibitory activity (IC₅₀: 158.94 μg/mL)
*GastroP↑, . Gastroprotective Effects of Carvacrol and Mechanism
*eff↑, . When combined with polysorbate 80 as a surfactant, carvacrol was efficiently deliveredto embryonic tissues, maintaining bioavailability during the peri-hatching phase
*BChE↓, acrol. The essential oil rich in carvacrol showedstrong inhibitory effects on AChE and butyrylcholinesterase (BChE) [
*CRP↓, d Phase II clinical trial, asthmatic patients whoreceived 1.2 mg/kg/day of carvacrol for two months showed significant improvements in pulmonaryfunction tests and a notable reduction in C-reactive protein levek

7338- Gra,    Pharmacological Activities of Soursop (Annona muricata Lin.)
- Review, Var, NA
AntiCan↑, A.muricata’s activities were shown to include anticancer (25%), antiulcer (17%), antidiabetic (14%), antiprotozoal (10%), antidiarrhea (8%), antibacterial (8%), antiviral (8%), antihypertensive (6%), and wound healing (4%).
*AntiDiabetic↑,
*Diar↓,
*Bacteria↓,
*AntiViral↑,
*Wound Healing↑,
MMP2↓, Fruit, stem, seed, and twigs Inhibits MMP-2 and MMP-9, which play an important role in cancer progression, in HT1080 fibrosarcoma cells.
MMP9↓,
MMP↓, Disrupts MMP function, reactive oxygen species (ROS) generation, and G0/G1 cell cycle arrest in HL-60 leukemia cells.
ROS↑,
TumCCA↑,
BAX↑, Increases Bax expression and decreases Bcl-2 expression, cell cycle arrest at G0/G1 phase in A-549 lung cancer cells.
Bcl-2↓,
Casp3↑, Induces apoptosis by enhancing the expression of caspase-3 in MDA-MB-231 breast cancer cells.
*BAX↓, Antiulcer Leaf, Downregulates Bax and malondialdehyde (MDA) expression.Upregulates CAT, SOD, GSH, NO, PGE2, glycogen, and Hsp70 expression.
*MDA↓,
*Catalase↑,
*SOD↑,
*GSH↑,
*NO↑,
*PGE2↑,
*HSP70/HSPA5↑,

7565- HYP,    Potential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review
- Review, AD, NA
*Inflam↓, exhibits a multitude of biological functions including anti-inflammatory, antidepressant, antioxidative, vascular protective effects and neuroprotective effects,
*antiOx↑,
*neuroP↑,
*lipid-P↓, Anti-oxidant Saccharomyces Cerevisiae 5, 20 mg/L Decreased LPO and the level of ROS
*ROS↓,
*IL1β↓, HT22 cells 20 μM Alleviates the level of IL-1β, IL-6, IL-8, TNF-α, ROS, MDA, Bax, and caspase-3; increases the expression of CAT, SOD, GSH, Bcl-2, BDNF, TrkB, and NGF.
*IL6↓,
*IL8↓,
*TNF-α↓,
*MDA↓,
*BAX↓,
*Casp3↓,
*Catalase↑,
*SOD↑,
*GSH↑,
*BDNF↑,
*TrkB↑,
*NGF↑,
*BDNF↑, Male Albino Swiss mice 0.94 mg/kg, 3.75 mg/kg Mediated by monoaminergic system and the upregulation of BDNF level
*NF-kB↓, Inhibited the activation of NF-κB, lessened the expression of iNOS,
*AChE↓, ICR mice 2.5 mg/kg Inhibited AchE activity
*H2S↑, SD rats 1, 10, 100 μM Upregulation of H2S,
Casp3↑, Anti-lung cancer A549 cells, Balb/c-nude mice 15, 20, 25 μM in vitro 15, 20, 25 mg/kg in vivo Activation of caspase-3 to motivate apoptosis and inactivation of NF-κB to inhibit inflammatory
Apoptosis↑,
NF-kB↓,
AMPK↑, A549 cells 10, 50, 100 μM Upregulation of AMPK signal pathway and HO-1 expression to suppressed the survival and proliferation of A549 cells
HO-1↑,
MAPK↑, A549 cells, H466 cells, C57BL/6J mice – Upregulated the expression of p38 MAPK, caspase 3, caspase 9, cleaved caspase 3, cleaved caspase 9 and Bax, downregulated the expression of Cu/Zn SOD, CAT, Nrf2, NQO1, HO-1 and Bcl-2
cl‑Casp3↑,
cl‑Casp9↑,
BAX↑,
SOD?,
Catalase↓,
NRF2↓,
NQO1↓,
HO-1↓,
Bcl-2↓,
TumCCA↑, A549 cells 10, 20, 50, 100, 200, 400 μg/mL Inhibited the process of G1/S phase to inhibit proliferation
FOXO1↑, NCI-H1975 cells, PC-9 cells, Nude male mice 30, 60, 90, 120, 150 μM in vitro, 25 mg/kg in vivo Upregulation of FoxO1
TumAuto↑, A549 cells 0.5, 1, 2 mM Induced autophagy through inhibiting the Akt/mTOR/p70S6K signal pathway
Akt↓,
mTOR↓,
P70S6K↓,
BMP7/OP1↓, HepG2 cells 5, 10, 20, 40, 80 μM Inhibiting the BMP-7
*cardioP↑, Cardiovascular Protective Effect
*hepatoP↑, Hepatoprotective
*antiCG↑, The report indicates hyperoside possesses antithrombotic activities and offer bases for development of a novel anticoagulant
*AntiThr↑,
*Diar↓, Antidiarrheal Activity
*AntiFungal↑, Antifungal Activity
*CYP2D6↓, hyperoside is a potent selective CYP2D6 inhibitor in HLMs, and might cause herb-drug interactions when co-administrated with CYP2D substrates.
*PDGFR-BB↓, In diabetic rats’ model, hyperoside inhibited the platelet-derived growth factor-BB (PDGF-BB)/platelet-derived growth factor-B receptor (PDGFR-β) ligand binding
*PDGFRB↓,
*toxicity↓, In research conducted in Wistar rats, the researchers demonstrated that in a long-term oral administration lasted for 6 months, hyperoside has a good safety. And the possible target organ of toxicity is kidney and the damage is reversible
*Half-Life↑, hyperoside also showed a long half-life for 4 hours and the safety experiments also proves that it has good safety.

6765- ProBio,    Probiotics
*GutMicro↑, hese mechanisms include the inhibition of the growth of pathogenic microorganisms in the gastrointestinal tract (by fostering colonization resistance, improving intestinal transit, producing antimicrobial substances, or helping normalize a perturbed
*AntiBio↑,
*pH↓, and the reduction of luminal pH in the colon
*Diar↓, Some systematic reviews and meta-analyses report that starting certain probiotic treatments within 2 days of the first antibiotic dose helps reduce the risk of antibiotic-associated diarrhea in specific patient populations.


Showing Research Papers: 1 to 9 of 9

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 9

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

BMP7/OP1↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 2,   GSH↓, 1,   HO-1↓, 2,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NQO1↓, 1,   NRF2↓, 1,   ROS↑, 2,   SOD?, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL4↑, 1,   AMPK↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   APAF1↑, 1,   Apoptosis↑, 2,   BAX↑, 3,   Bcl-2↓, 3,   Casp3↓, 1,   Casp3↑, 2,   cl‑Casp3↑, 1,   Casp9↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↓, 1,   iNOS↓, 1,   JNK↓, 1,   p‑JNK↓, 1,   MAPK↓, 1,   MAPK↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP27↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1↑, 1,   LC3I↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD44↓, 1,   ERK↓, 1,   FOXO1↑, 1,   mTOR↓, 1,   P70S6K↓, 1,  

Migration(tgid=13) ⓘ

MMP2↓, 1,   MMP9↓, 1,   β-catenin/ZEB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   ICAM-1↓, 1,   IFN-γ↓, 1,   IL2↓, 1,   IL4↓, 1,   Imm↑, 1,   NF-kB↓, 3,   NK cell↑, 1,   PGE2↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↝, 2,   eff↑, 1,   RadioS↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   radioP↑, 1,   Weight↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

Diar↓, 2,  
Total Targets: 66

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiArt↑, 1,   AntiBio↑, 1,   antiCG↑, 1,   CYP2D6↓, 1,   Dysb↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   Catalase↑, 2,   GSH↑, 2,   lipid-P↓, 1,   MDA↓, 2,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 2,   VitC↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

H2S↑, 1,  

Cell Death(tgid=5) ⓘ

BAX↓, 2,   Casp3↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

TRPV3↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 1,   other↝, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP70/HSPA5↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

PDGFRB↓, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,   AntiAg↑, 1,   Ca+2↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↑, 1,   PDGFR-BB↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GastroP↑, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   CRP↓, 1,   IL1β↓, 1,   IL6↓, 1,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 4,   NF-kB↓, 1,   PGE2↑, 1,   TNF-α↓, 1,  

Cellular Microenvironment(tgid=17) ⓘ

pH↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 2,   BChE↓, 1,   BDNF↑, 2,   NGF↑, 1,   TrkB↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   Dose↝, 1,   eff↑, 2,   Half-Life↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

CRP↓, 1,   GutMicro↑, 2,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiDiabetic↑, 1,   cardioP↑, 3,   chemoPv↑, 1,   cognitive↑, 1,   hepatoP↑, 2,   neuroP↑, 2,   Pain↓, 2,   toxicity↓, 2,   Wound Healing↑, 3,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   AntiViral↑, 1,   Bacteria↓, 2,   Diar↓, 7,  
Total Targets: 66

Scientific Paper Hit Count for: Diar, Diarrhea
2 Carvacrol
1 Phyllanthus emblica/Emblica officinalis/Amla / Indian Gooseberry
1 Bifidobacterium
1 Bromelain
1 Bruteridin(bergamot juice)
1 Graviola
1 Hyperoside
1 probiotics
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1456  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page